Posted by Michael Wonder on 24 May 2021
Almirall receives positive CHMP opinion for Klisyri (tirbanibulin), an innovative topical treatment for actinic keratosis
21 May 2021 - Klisyri (tirbanibulin) is a novel microtubule inhibitor, indicated for the topical treatment of actinic keratosis of the face or scalp and it acts through a selective anti-proliferative mechanism of action.
Almirall announced today that the CHMP of the EMA has issued a positive opinion for the regulatory approval of Klisyri (tirbanibulin) for the topical treatment of actinic keratosis on the face or scalp.
